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Background: The irradiation of head and neck cancer (HNC) often causes damage to the 
salivary glands. The resulting salivary gland hypofunction and xerostomia seriously reduce 
the patient’s quality of life.
Purpose: To analyze the literature of actual management strategies for radiation-induced 
hypofunction and xerostomia in HNC patients.
Methods: MEDLINE/PubMed and the Cochrane Library databases were electronically 
evaluated for articles published from January 1, 1970, to June 30, 2013. Two reviewers inde-
pendently screened and included papers according to the predefined selection criteria.
Results: Sixty-one articles met the inclusion criteria. The systematic review of the literature 
suggests that the most suitable methods for managing the clinical and pathophysiological con-
sequences of HNC radiotherapy might be the pharmacological approach, for example, through 
the use of cholinergic agonists when residual secretory capacity is still present, and the use of 
salivary substitutes. In addition, a modified diet and the patient’s motivation to enhance oral 
hygiene can lead to a significant improvement.
Conclusion: Radiation-induced xerostomia could be considered a multifactorial disease. It 
could depend on the type of cancer treatment and the cumulative radiation dose to the gland 
tissue. A preventive approach and the correct treatment of the particular radiotherapeutic patient 
can help to improve the condition of xerostomia.
Keywords: radiation-induced xerostomia, salivary gland hypofunction, management 
strategies
Introduction
Xerostomia is a term used to describe the subjective symptoms of a dry mouth 
deriving from a lack of saliva. A large variety of causes can lead to xerostomia, eg, 
radiotherapy and chemotherapy,1–4 the chronic use of drugs,5–7 and rheumatic and 
dysmetabolic diseases.8,9
Saliva is an important host defense component of the oral cavity. Major salivary 
glands contribute to most of the secretion volume and electrolyte content of saliva 
(the parotid, submandibular, and sublingual glands, which account for 90% of saliva 
production), whereas minor salivary glands contribute little secretion volume and 
most of the blood-group substance.10 Saliva components interact in related functions 
in the following general areas:
1) bicarbonates, phosphates, and urea act to modulate pH and the buffering capacity 
of saliva;
2) macromolecule proteins and mucins serve to cleanse, aggregate, and/or attach oral 
microorganisms and contribute to the dental plaque metabolism;
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3) calcium, phosphates, and proteins work together as an 
antisolubility factor and modulate demineralization and 
remineralization of tooth surfaces;
4) immunoglobulins, proteins, and enzymes provide anti-
bacterial action.
Objectively, patients affected by xerostomia have a 
hypofunction of the salivary output11,12 leading to functional 
oral disorders such as sore throat, altered taste, dental decay, 
changes in voice quality, and impaired chewing and swallow-
ing function.13 These factors may ultimately cause reduced 
nutritional intake and weight loss and significantly affect 
general health and quality of life of the subjects involved.
Head and neck cancer (HNC) actually includes many 
different malignancies. The most common type of cancer 
in the head and neck is squamous cell carcinoma, which 
originates in the cells that line the inside of the paranasal 
sinuses, nasal cavity, salivary glands, oral cavity, esopha-
gus, pharynx, and larynx.14 Worldwide, lip and oral cavity 
cancer along with thyroid cancer has the highest incidence; 
esophagus cancer is the most aggressive presenting a 4.9% 
mortality rate (Table 1).
Similar findings regarding the incidence, mortality, 
and prevalence of cancer in the European Union have been 
reported. The highest mortality rate belongs again to esopha-
gus cancer with a predominance of 2.3% (Table 2).
Other less common types of HNCs include salivary gland 
tumors, lymphomas, and sarcomas.15
The way a particular HNC behaves depends on the 
primary site in which it arises, and the spread to the lymph 
nodes in the neck is relatively common.
A patient may receive radiotherapy before, during, or 
after surgery. Some patients may receive radiotherapy alone 
without surgery or any other treatment; others may receive 
radiotherapy and chemotherapy at the same time. The tim-
ing of radiotherapy depends on the type of cancer and on 
the goal of the treatment (cure or palliation). Radiotherapy 
treats cancer by using doses of high-energy X-rays to destroy 
the cancer cells while avoiding as much harm as possible to 
normal cells. The treatment is usually given every weekday 
with a pause at the weekend; some protocols are based on 
more than one irradiation a day, and occasionally include 
therapy during the weekend. The treatment will usually last 
3–7 weeks, depending on the type and size of the cancer. 
Most of the time, patients with HNC treated with radiotherapy 
receive a dose between 50 Gy and 70 Gy once a day for 
5 days a week (2 Gy per fraction);4 on the other hand, if the 
radiotherapy protocol is just preoperative, the total amount 
of radiation is usually lower. Conformal radiotherapy is the 
most common type of radiotherapy used for the treatment 
of HNC; a special attachment to the radiotherapy machine 
carefully arranges the radiation beams to match the shape of 
the cancer, reducing the radiation to the surrounding healthy 
cells. Another similar type of radiotherapy used against HNC, 
known as intensity-modulated radiotherapy, allows a more 
accurate delivery of specific radiation to be distributed to the 
tumor mass according to its location and severity, sparing the 
tissue and organs at risk, eg, salivary glands.10
Aims
The aim of the study is to systematically determine the current 
treatment option for cancer-/radiation-induced xerostomia 
among patients treated for HNC, and to describe the strategic 
prevention and management enhancements.
Materials and methods
Systematic review methodology
Search strategy
A first systematic literature search for articles published 
between January 1, 1970 and June 30, 2013 was conducted 
in the databases MEDLINE/PubMed and the Cochrane 
Library, using combinations of the MeSH terms: [Saliva] 
OR [Salivary Glands] OR [Saliva Flow] OR [Salivation] 
OR [Salivary Gland Diseases] OR [Xerostomia] OR 
[Saliva in Xerostomia] OR [Dry Mouth] OR [Oral Dryness] 
Table 1 world incidence, mortality, and 5-year prevalence of head and neck cancer
Cancer Incidence Mortality 5-year prevalence
Number % ASR (W) Number % ASR (W) Number % Proportion
Lip, oral cavity 300,373 2.1 4.0 145,328 1.8 1.9 702,149 2.2 13.5
Nasopharynx 86,691 0.6 1.2 50,828 0.6 0.7 228,698 0.7 4.4
Other pharynx 142,387 1.0 1.9 96,090 1.2 1.3 309,991 1.0 6.0
esophagus 455,784 3.2 5.9 400,156 4.9 5.0 464,063 1.4 8.9
Larynx 156,877 1.1 2.1 83,376 1.0 1.1 441,675 1.4 8.5
Thyroid 298,102 2.1 4.0 39,769 0.5 0.5 1,206,075 3.7 23.2
Notes: % = risk of getting or dying from the disease before age 75.
Abbreviation: ASR, age-standardized rate.
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OR [Composition Saliva Xerostomia] AND [Head and 
Neck Cancer] OR [Radiotherapy] OR [Radiation-induced 
Xerostomia] OR [Parotid-Sparing Intensity-Modulated 
Radiotherapy] AND [Quality of Life Analysis-Xerostomia] 
OR [Management Strategies Salivary Gland Hypofunction] 
OR [Prevention Xerostomia] OR [Treatment Xerostomia]. 
The search results were imported into a computerized data-
base Review Manager 5.2. The search results from each 
of the electronic databases of MEDLINE/PubMed and the 
Cochrane Library were combined, and duplicated publica-
tions were eliminated. Subsequently, an update to include 
studies published up to June 30, 2013, was performed.
Criteria for selecting studies
After completing the search, articles for review were selected 
based on:
•	 English language
•	 Original data of cancer therapy protocols
•	 Oral complications associated with cancer therapies
•	 Human.
exclusion criteria
The reasons for exclusion were defined as follows:
•	 Studies without original and/or actual data
•	 Studies with data from previous publications
•	 Opinion papers
•	 Editorials.
In this way, a preliminary set of potentially relevant 
publications, removing irrelevant citations according to 
the criteria, was created. Two reviewers (RP and GC) inde-
pendently screened the registered title and abstracts, and 
author and references in two separate files (one for included 
abstracts and one for excluded abstracts) using a screening 
guide based on eligibility criteria. Studies rejected at this 
stage or subsequent stages were reported in the table of 
excluded studies (Table 3). The full text of all potentially 
eligible studies in at least one screening was retrieved. 
Reviewers then evaluated the full text for inclusion using 
a screening guide and a second reviewer (RP) screened 
all the findings. When disagreement occurred, a third 
reviewer (IM) was consulted. For each review, the follow-
ing information was recorded: year, authors, journal, aim, 
and number of papers reviewed (Table 4); and for clinical 
trial papers included: year, authors, journal, aim, number 
of patients, and results (Table 5). All studies meeting the 
inclusion criteria then underwent validity assessment. Two 
examiners (RP and GC) read the papers independently. 
The qualities and relevance of each study were graded 
as follows: high (+++), medium (++), or low (+) using a 
study-quality checklist. External validity, internal valid-
ity, and study precision were analyzed to obtain an overall 
assessment of quality. The assessment was used as a basis 
for the discussion between the two examiners to grade the 
studies. In the case of disagreement, all authors discussed 
the paper until a consensus was reached.
Results
The electronic searches identified about 1,000 titles and 
abstracts, and after reviewing the titles, 411 studies were 
evaluated. Subsequently, during the review of the abstract, 
336 studies were excluded. The final analysis included 
70 articles that conformed to the criteria for the present 
review (Figure 1). Although animal studies have been 
excluded, important information regarding the experimen-
tal results on two of the papers was considered useful and 
therefore they were discussed.
Table 2 european Union incidence, mortality, and 5-year prevalence of head and neck cancer
Cancer Incidence Mortality 5-year prevalence
Number % ASR (W) Number % ASR (W) Number % Proportion
Lip, oral cavity 43,847 1.6 4.9 14,467 1.1 1.5 121,633 1.7 28.4
Nasopharynx 3,267 0.1 0.4 1,494 0.1 0.2 9,283 0.1 2.2
Other pharynx 26,585 1.0 3.2 12,583 1.0 1.4 67,590 0.9 15.8
esophagus 34,777 1.3 3.4 29,845 2.3 2.8 38,086 0.5 8.9
Larynx 28,336 1.1 3.1 12,248 1.0 1.2 94,193 1.3 22.0
Thyroid 37,440 1.4 5.4 3,637 0.3 0.3 149,044 2.1 34.8
Note: % = risk of getting or dying from the disease before age 75.
Abbreviation: ASR, age-standardized rate.
Table 3 Papers excluded
Reference Year Authors Journal Reason
19 1991 vissink et al J Oral Pathol Med Animal study
70 1998 Davies Br Med J editorial
46 1998 Spielman J Dent Res Animal study
51 2000 Kuntz et al Int J Pharm Compound Opinion paper
3 2005 waltimo et al Schweiz Monatsschr 
Zahnmed
Article in 
German
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Table 4 Reviews included
Reference Year Authors Journal Aim Number of papers 
reviewed
Qualities and 
relevance of studies 
included score
23 1977 Dreizen et al Postgrad Med Narrative – To evaluate the main injury of the 
surrounding tissues during radiotherapy for oral 
cancer that can have devastating physical and 
psychological consequences for the patients
13 ++
45 1994 Atkinson and 
wu
J Am Dent 
Assoc
Narrative – To evaluate the three most common 
known causes (medication, radiotherapy, and 
Sjögren’s syndrome) of salivary gland dysfunction 
and their clinical management
62 +++
17 1996 Scully and 
epstein
Eur J Cancer B 
Oral Oncol
Narrative – To discuss the etiopathogenesis 
and current means available for preventing, 
ameliorating, and treating radiotherapy 
complications, as well as indicating research 
directions
282 +++
1 1998 Bivona N Y State 
Dent J
Narrative – To evaluate generally 
physiopathological features and clinical 
management of Sjögren’s syndrome
16 ++
61 2000 Dyke Int J Pharm 
Compound
Narrative – To evaluate physiopathological 
features and clinical management of Sjögren’s 
syndrome
19 +
18 2000 Sreebny Int Dent J Systematic – This paper reviews the role of 
saliva, the prevalence of oral dryness, and 
consequent importance of salivary flow as well 
as the relationship between xerostomia and 
salivary gland hypofunction among the causes of 
oral dryness. Other aspects: association between 
saliva and Sjögren's syndrome and esophageal 
function; use of saliva as diagnostic tool
134 +++
47 2002 Pedersen et al Oral Dis Narrative – This paper reviews the role of 
human saliva and its compositional elements 
in relation to the gastrointestinal functions of 
taste, mastication, bolus formation, enzymatic 
digestion, and swallowing
161 +
2 2003 Cassolato and 
Turnbull
Gerodontology Narrative – To outline for clinicians the 
common etiologies, clinical identification, and 
routine therapeutic modalities available for 
individuals with xerostomia
86 +++
12 2004 Porter et al Oral Surg Oral 
Med Oral 
Pathol Oral 
Radiol Endod
Narrative – To create an update of the etiology 
and management of xerostomia
229 +++
14 2008 Argiris et al Lancet Narrative – To review the epidemiology, 
molecular pathogenesis, diagnosis and staging, and 
the latest multimodal management of squamous 
cell carcinoma of the HNC
153 +++
63 2008 Sagar Curr Treat 
Options Oncol
Narrative – To describe the effectiveness of 
acupuncture to control the symptoms of cancer 
patients, with an evidence-based approach
59 ++
55 2010 Ramos-Casals 
et al
JAMA Systematic – To summarize evidence on 
primary Sjögren’s syndrome drug therapy from 
randomized controlled trials
74 +
10 2010 Jensen et al Support Care 
Cancer
Systematic – To assess the literature for 
management strategies and economic impact 
of salivary gland hypofunction and xerostomia 
induced by cancer therapies and to determine 
the quality of evidence-based management 
recommendations
154 +++
(Continued)
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Physiopathological and clinical 
consequences in cancer therapy
Each of the reviews concerning the physiopathological and 
clinical consequences are listed in Table 6.
Physiopathological consequences
A total of six articles reported the physiopathological effects 
of radiotherapy on salivary glands parenchyma: one system-
atic review, one narrative review, one pilot study, one animal 
experimentation study, and one cohort study.16–20 Radiotherapy-
induced xerostomia could be considered a multifactorial dis-
ease. On the one hand, the damage to the oral cavity has been 
strongly related to the radiation dose, fraction size, volume of 
irradiated tissue, fractionation scheme, and type of ionizing 
irradiation, but on the other, it may be difficult to distinguish 
changes caused by radiotherapy itself from those related to the 
malignant disease, the concomitant systemic diseases, and the 
medication needed for the treatment of the cancer.16,17
The salivary glands are superficially located compared to 
most head and neck tumors, and thus, the ionizing radiation 
has to pass through the salivary glands to effectively treat the 
tumor.18 Tissues with a rapid turnover rate are more susceptible 
than tissues with a slow one and even with the most accurate 
therapeutic protocol, X-rays cause unwanted changes in 
non-tumoral tissues. Despite the fact that salivary gland cells 
turnover is slow, production and quality of saliva change after 
radiation, so they are not as radioresistant as they are supposed 
to be.19 There are differences among the various types of sali-
vary glands; in fact, the submandibular gland is less radiosensi-
tive than the parotid gland.20 From this point of view, the most 
severe and irreversible forms of salivary gland hypofunction 
result from the damage/loss of salivary acinar cells, giving rise 
to rapid and predictable compositional changes, and reduction 
in saliva production and in the quality of the flow.
Radiation-induced changes in saliva
Nineteen articles analyzed the effects of the radiotherapy on sal-
ivary flow and composition, and the changes in microbial popu-
lation: one narrative review, four randomized controlled trials, 
nine cohort studies, and five cross-sectional studies.21–40
Salivary flow
One of the main problems resulting from tissue damage gen-
erated by radiotherapy is the reduction of salivary flow. The 
radiation level necessary to cause severe dysfunction to gland 
tissue is 52 Gy. Below this threshold, the radiation damage 
generally has a transient and reversible duration.12 Routinely, 
HNC patients receive a total of 50–70 Gy, the radiation dose 
normally used to destroy malignant cells, which very often 
leads to the onset of chronic xerostomia.21 The major reduc-
tion in salivation after radiotherapy is observed in the period 
from the onset of radiotherapy to 3 months after completion. 
During radiotherapy, the first 10 days are the worst ones as a 
massive decrease in saliva production occurs; especially in the 
first week, it could reduce by 50%–60%.22 After this period, 
the flow rate is reduced by 10% of the initial conditions.23
Chemical and immunochemical alterations
Radiotherapy can also induce alterations in electrolytes 
and antibacterial systems. Salivary electrolyte levels are 
Table 4 (Continued)
Reference Year Authors Journal Aim Number of papers 
reviewed
Qualities and 
relevance of studies 
included score
10 2010 Jensen et al Support Care 
Cancer
Systematic – To assess the literature for 
prevalence, severity, and impact on quality of life 
of salivary gland hypofunction and xerostomia 
induced by cancer therapies
203 +++
66 2010 O’Sullivan and 
Higginson
Acupunct Med Systematic – To systematically review 
evidence on clinical effectiveness and safety of 
acupuncture in irradiation-induced xerostomia in 
patients with HNC
51 +++
41 2013 Radvansky 
et al
Am J Health 
Syst Pharm
Narrative – To evaluate current strategies for 
preventing and managing radiation-induced 
dermatitis, mucositis, and xerostomia, with an 
emphasis on pharmacologic interventions
52 ++
67 2013 Zhuang et al Integr Cancer 
Ther
Systematic – To evaluate the preventive and 
therapeutic effect of acupuncture for radiation-
induced xerostomia among patients with HNC
46 +++
Notes: +++, high level; ++, medium level; +, low level.
Abbreviation: HNC, head and neck cancer.
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altered, with an increase in the concentrations of sodium, 
chloride, calcium, and magnesium, while potassium is 
only slightly affected.24 Saliva also reduces the buffering 
capacity in irradiated patients due to a reduction of bicar-
bonate concentration in parotid saliva.25,26 Saliva becomes, 
moreover, highly viscous, and reduces its pH from about 
7.0 to 5.025,27 with slow recovery to the neutral pH in 
dental plaque after a sugar rinse.28,29 The permanence of 
the acidic pH in dental plaque was related to the reduced 
buccal gland saliva flow30 as the secretion from the buc-
cal glands, closely delivered to the teeth surfaces, could 
affect the dental plaque more than the whole saliva during 
resting conditions.
Changes also involve the nonimmune and immune anti-
bacterial systems. The concentrations of immunoproteins 
(eg, secretory immunoglobulin A), lysozyme, and lactofer-
rin are increased, as well as the serum and non-salivary 
components.31–34 However, the decrease in salivary flow rate 
is greater than the increase in immunoprotein and lysozyme 
levels, and this results in significant immunoprotein deficit. 
Since the reduction of the oral clearance, immunologic 
mechanisms and buffering capacity of saliva are altered, 
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Figure 1 Search flowchart.
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and on the subsequent development of dental caries.35 Five 
intraoral specimens consisting of resting saliva, gingival 
sulcus fluid, dental plaque, lingual swabs, and stimulated 
whole saliva were collected from each patient two times 
during 1 week before radiation, one time per week during 
radiotherapy, at 3-month intervals during the first postra-
diation year, and at 6-month intervals thereafter. During 
irradiation, the development of xerostomia was matched by a 
parallel and pronounced shift in certain microbial populations 
at each intraoral site assessed. The most prominent changes 
were the increase in S. mutans and species of Lactobacillus, 
Candida (primarily Candida albicans), and Staphylococcus, 
with parallel decreases in Streptococcus sanguis and species 
of Neisseria and Fusobacterium. Microbial differences were 
Table 6 Reviews included related to physiopathological and clinical consequences in cancer therapy
Reference Year Authors Journal Aim Number of papers  
reviewed
Qualities and  
relevance  
of studies  
included score
Physiopathological consequences
17 1996 Scully and  
epstein
Eur J Cancer B  
Oral Oncol
Narrative – To discuss the etiopathogenesis  
and current means available for preventing, 
ameliorating, and treating these complications,  
as well as indicating research directions
282 +++
18 2000 Sreebny Int Dent J Systematic – This paper reviews the role 
 of saliva, the prevalence of oral dryness,  
and consequent importance of salivary flow  
as well as the relationship between xerostomia  
and salivary gland hypofunction among the causes  
of oral dryness. Other aspects: associations 
between saliva and Sjögren's syndrome and 
esophageal function; use of saliva as diagnostic tool
134 +++
Radiation-induced changes of saliva
23 1977 Dreizen et al Postgrad Med Narrative – To evaluate the main injury  
to surrounding tissues during radiotherapy 
 for oral cancer that can have devastating  
physical and psychological consequences 
 for the patients
13 ++
Radiotherapy clinical consequences
45 1994 Atkinson and  
wu
J Am Dent  
Assoc
Narrative – To evaluate the three most  
common known causes (medication,  
radiotherapy, and Sjögren’s  
syndrome) of salivary gland dysfunction 
 and their clinical management
62 +++
47 2002 Pedersen et al Oral Dis Narrative – This paper reviews the role of  
human saliva and its compositional elements  
in relation to the gastrointestinal functions of  
taste, mastication, bolus formation, enzymatic 
digestion, and swallowing
161 +
41 2013 Radvansky et al Am J Health  
Syst Pharm
Narrative – To evaluate current strategies  
for preventing and managing radiation- 
induced dermatitis, mucositis, and xerostomia,  
with an emphasis on pharmacologic interventions
52 ++
Notes: +++, high level; ++, medium level; +, low level.
and the host protection decreases giving rise to changes in 
the oral flora.35
Microbial changes
All of these radiation-induced changes cause a different 
oral flora growth and acidogenic, cariogenic microorgan-
isms are more present than non-cariogenic microorganisms. 
Unfortunately, even if there is an increase in immunoprotein 
and lysozyme levels, a significant immunoprotein deficit 
occurs due to the decrease in salivary flow rate. Streptococ-
cus mutans, Lactobacillus spp., and Candida spp. are the 
most prevalent in the plaque of irradiated patients.30,36–38 
In a longitudinal study, Brown et al assessed the effects of 
radiation-induced xerostomia on the human oral microflora 
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relatively minimal between the groups of patients receiving 
radiotherapy who used a fluoride gel and a nonfluoride gel 
during the irradiation period. However, there was a more 
rapid decrease in the level of S. sanguis in the plaque of 
the patients using the nonfluoride gel compared with those 
patients using the fluoride gel, and the subsequent develop-
ment of dental caries differed greatly. The increased number 
of Lactobacilli was correlated to a high acidic potential of 
the plaque and the use of fluoride was associated with a 
protective effect in the prevention of dental decay during 
xerostomia.
The findings that a high frequency, number, and propor-
tion of Lactobacillus spp. occur in irradiated patients were 
strengthened by a study of Almståhl et al who analyzed the 
saliva oral microbiota in subjects with hyposalivation using 
a rinsing technique and a cultivation technique. Results 
indicated that the salivary secretion rate, pH, and buffer 
capacity were the more important factors in the increase in 
Lactobacillus spp. A marked increase in C. albicans was also 
characteristic of the irradiated patients.39
In a more recent study, Almståhl et al evaluated the 
frequency of different Lactobacillus spp. in relation to the 
pH-lowering potential of the supra-gingival plaque in irradi-
ated patients in comparison to primary Sjögren’s syndrome 
patients and controls with normal salivary secretion.40 The 
irradiated subjects had finished their bilateral radiation treat-
ment (64.6 Gy) 3–5 years before participating in the study. 
Interproximal plaque pH was measured by the microtouch 
method30 before and up to 60 minutes after a 10% sugar 
rinse.29 The measurements were performed at two sites: in 
the anterior and in the premolar/molar region. Data indicated 
that the most common species were Lactobacillus fermen-
tum, Lactobacillus rhamnosus, and Lactobacillus casei. In 
anterior sites, both the hyposalivated group subjects with 
high Lactobacillus counts had an increased plaque acidoge-
nicity compared to those with low counts. In posterior sites, 
subjects with high Lactobacillus counts had a lower final pH 
compared with those with low counts. Authors concluded 
that hyposalivation patients often harbor several different 
Lactobacillus spp. in their supragingival plaque. There were, 
however, large differences in number and proportion of 
Lactobacilli between individuals and between anterior and 
posterior dental sites, but no specific species could be related 
to plaque acidogenicity.
Radiotherapy clinical consequences
In eleven articles, the clinical consequences that may arise 
as a result of HNC radiotherapy have been described: three 
narrative reviews, one randomized clinical trial, one animal 
experimentation study, four cohort studies, and two cross-
sectional studies.20,36,41–50 Radiotherapy can cause some 
temporary side effects. Although these may be worse if the 
treatment is combined with chemotherapy, they gradually 
disappear after the treatment has finished. Most radiotherapy 
side effects occur toward the middle and end of the course of 
treatment and continue during the first couple of weeks after 
the treatment. The effects can be mild or more troublesome, 
depending on the dose of radiotherapy and the length of treat-
ment. Thus, the quantitative and qualitative salivary changes 
predispose the irradiated patient to a variety of problems.
Radiotherapy in HNC is inevitably associated with 
damages to the oral tissues and, in addition, the clinical 
consequences of radiotherapy include also dermatitis and 
osteoradionecrosis.41 In fact, salivary glands are often 
involved and, as a result, patients may have a salivary gland 
hypofunction, even if 3D planning and unilateral irradiation 
have considerably reduced the side effects by minimizing the 
dose to normal tissues. However, the final degree of damage 
to gland tissue depends on individual patient characteristics, 
such as pretreatment already done, age, and sex.
Xerostomia may affect 80% of the patients who need 
radiotherapy as a primary treatment, as an adjunct to surgery, 
in combination with chemotherapy, or as palliation.42–44 
Hyposalivation represents the biggest acute side effect in 
HNC radiotherapy and, in general, is always associated with 
oral function problems, such as chewing and swallowing, 
or caries at a later stage. Normally, during radiotherapy, 
salivary composition may change and it becomes more 
viscous than usual, so its color may turn yellow, brown, or 
even white (Figure 2). Furthermore, salivary glands with 
high flow rates before the initiation of radiotherapy show 
less reduction in salivary flow rate. As a consequence of the 
reduction in the rate of saliva flow, which is correlated to 
the amount of radiation given to the patient, oral complica-
tions occur.20
The buccal mucosa has a dry and sticky appearance 
(Figure 3). The normally moist, glistening appearance of 
the oral cavity is often replaced with a thin, pale, cracked 
appearance that is more susceptible to gingivitis and bleed-
ing. Another frequent acute side effect is oral mucositis, 
which can be experienced by 50% of patients receiving 
HNC radiotherapy. Some typical side effects are onset of 
erythema, edema, and pain in the oral mucosa.41 Patients 
may also exhibit a dry irritated tongue with an erythematous 
appearance of the dorsal surface, the hard or soft palate, the 
commissures of the mouth, and under-removable prostheses.43 
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Furthermore, the lack of saliva may lead to angular cheilitis, 
cracked lips (Figure 4), periodontal disease, aching of the 
mouth, and halitosis.
When part or all of the mouth is treated, the sense of 
taste may change quickly during the radiotherapy, and some 
patients may even either lose their sense of taste completely 
or find that everything tastes the same (usually rather metallic 
or salty). Changes in taste are correlated to the direct irradia-
tion of the taste buds, and also to the reduction in salivary 
flow rate that alters the ionic composition of saliva that is 
related to the sensation of taste.46
Moreover, the loss of saliva compromises mastication 
and nutrition. Some patients lose their appetite as a general 
effect of radiotherapy. Dryness of the mouth and lips can 
cause discomfort, ranging from a mild irritation to a severe 
burning sensation with difficulties in normal eating habits, 
particularly eating spicy or acidic food. A sore, dry mouth can 
also make eating and swallowing difficult because moistening 
of food is insufficient and oral mucosa surfaces are not wet 
and not lubricated enough.47
Furthermore, an insufficient lubrication, due to a dimin-
ished salivary output, causes intolerance to prosthetic appli-
ances, so more friction is present between the mucosa and 
the resin that can injure the delicate irradiated epithelial 
layer. In addition, the inadequate presence of saliva weak-
ens the stability of prostheses in the mouth. Ulceration is 
more likely because the dry mucosa is more vulnerable to 
trauma.
A further complication that tends to occur later in irradi-
ated patients is the increased risk of developing dental caries 
and oral infections, due to the alterations in the saliva flow 
and consequently in oral microflora.36 The decay is most 
often recurrent or primary and located at sites generally not 
usually susceptible to caries such as the cervical margins, 
incisal margins, or the tips of teeth (Figure 4).
Another issue is the high incidence of yeast infections 
during xerostomia.48 An example being the C. albicans infec-
tion, which is very common in both dentate and edentulous 
individuals and allows a colonization of oral mucosae49 
increasing the risk of oral mucosal infections.50
Another acute side effect of radiotherapy is dermatitis, 
which can be experienced by up to 95% of patients.41 The 
skin over the face and neck is very likely to gradually redden 
or darken and become sore. At the same time, the mouth and 
throat become sore and inflamed after a couple of weeks of 
treatment and mouth ulcers may occur; the voice may also 
become hoarse.
Discussion
The treatment of xerostomia has four aims: increasing exist-
ing saliva flow or replacing lost secretions, the control of 
the state of oral health, the control of dental caries, and the 
treatment of possible infections.51
Therapy options in xerostomia depend on the presence 
of residual secretion or the absence of it. When residual 
Figure 2 viscous appearance of the saliva in a radiotherapeutic patient.
Figure 3 Dry and sticky appearance of oral mucosa in a radiotherapeutic patient.
Figure 4 Cheilitis and cracked lips, and teeth cervical caries in a radiotherapeutic patient.
Therapeutics and Clinical Risk Management 2015:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
185
Xerostomia induced by radiotherapy
secretory capacity is present, it is advisable to regularly 
stimulate the salivary glands by mechanical or gustatory 
stimuli as supportive oral care. The use of sugarless chewing 
gum or candy-containing xylitol or sorbitol can be recom-
mended as a means of stimulating extra salivary flow to aid 
caries management and lubrication. Nocturnal oral dryness 
can be alleviated by applying a small amount of dentifrice 
on smooth dental surfaces, especially using anti-xerostomia 
dentifrices that contain three salivary enzymes, lactoperoxi-
dase, glucose oxidase, and lysozyme, specifically formulated 
to activate intraoral bacterial systems.
The salivary flow can also be stimulated by the use of 
cholinergic pharmaceutical preparations, such as pilocarpine 
or cevimeline. These two parasympathomimetic drugs are 
approved by the Food and Drug Administration for treat-
ment of xerostomia; pilocarpine is approved for Sjögren’s 
syndrome and radiotherapy-induced xerostomia, while 
cevimeline seems to be more specific for Sjögren’s syndrome. 
Pilocarpine, a natural alkaloid, is a parasympathomimetic 
agent with β-adrenergic effects that activates cholinergic 
receptors,52 stimulating the residual function of the salivary 
glands. The recommended dose is 5 mg orally three times a 
day.53 Severe adverse effects are rare, but side effects associ-
ated with the use of the drug are vomiting, sweating, head-
ache, increased urinary frequency, wheezing, watery eyes, 
and nausea, and gastrointestinal intolerance. Hypotension, 
rhinitis, diarrhea, and visual disturbances can also occur.54,55 
Normally, these are moderate in intensity and last for a short 
period of time. Patients with asthma, high blood pressure, 
heart diseases, and in therapy with β-blockers cannot use 
pilocarpine because this drug is a nonselective antagonist of 
muscarinic receptors and, therefore, it can interfere with the 
cardiac and respiratory functions in those patients. For the 
same reason, pilocarpine, stimulating muscarinic receptors 
in the central nervous system, can cause onset of agitation, 
confusion, and parkinsonian-like syndromes.56
Cevimeline is analogous to acetylcholine, which binds 
to muscarinic acetylcholine receptors in exocrine glands, 
specifically the M1 and M3 subtypes present, for instance, 
in the epithelium of the salivary and lachrymal glands, 
leading to an increase in exocrine gland secretion including 
saliva and sweat. M2 and M4 receptor sites predominate 
in cardiac and respiratory tissues. This receptor subtype 
selectivity is presumed to mitigate the systemic adverse 
effects of muscarinic–cholinergic stimulation.56 It is rapidly 
absorbed from the gastrointestinal tract, reaching peak con-
centrations in approximately 90 minutes without food. The 
duration of its sialogogic effect seems to be unclear. Clinical 
trials have shown it to be more effective than placebos in 
relieving the symptoms of a dry mouth. The recommended 
dose is 30 mg orally three times a day, but in two clinical 
trials, it has been shown that the use of cevimeline in treat-
ing radiation-induced xerostomia, increasing the dose to 
45 mg, was well tolerated by patients, with an increase of 
unstimulated salivary flow.57,58 This medication is not recom-
mended for patients with uncontrolled asthma, narrow-angle 
glaucoma, or iritis. Excessive sweating and nausea are the 
most frequently reported adverse effects with cevimeline. 
Rhinitis, diarrhea, and visual disturbances, especially at 
night, can also occur.
Another medication is anethole trithione that is a bile 
secretion-stimulating drug, or cholagogue. It increases the 
secretion of acetylcholine and stimulates the parasympathetic 
nervous system, and so as a result, we have the stimulation of 
salivation from serous acinar cells. This medication has been 
used for many years in the treatment of chronic xerostomia, 
but reports differ regarding its efficacy. While some studies 
report improvements in salivary flow rates in drug-induced 
xerostomia, trials in patients with Sjögren’s syndrome show 
conflicting results. Side effects reported include abdominal 
discomfort and flatulence. Dosages of 75 mg three times daily 
may be effective in treating patients with mild-to-moderate 
symptoms of xerostomia, but further research is needed to 
establish its safety and efficacy in this setting.59
Yohimbine has also been used in patients with xeros-
tomia and it is an alpha-2 adrenergic antagonist, which 
induces an increase in cholinergic activity peripherally. In 
one randomized, double-blind, crossover study, the effect of 
this medication was compared to that of anethole trithione 
in patients treated with psychotropic medications. Patients 
given yohimbine 6 mg three times daily for 5 days showed 
significantly increased saliva flow (P0.01) when compared 
with anethole trithione 25 mg three times daily.60
Human interferon alfa (IFN-α) is currently undergoing 
clinical trials to determine the safety and efficacy of low-
dose lozenges in the treatment of salivary gland dysfunction 
and xerostomia. In one study, IFN-α lozenges at dosages 
of 150 IU given three times daily for 12 weeks resulted in 
a significant increase in stimulated whole saliva (P=0.04) 
when compared with placebos.61
If some residual function of salivary glands remains, 
acupuncture could be a good alternative treatment for alle-
viating radio-induced xerostomia.62 The way this works 
remains poorly understood, but it seems that acupuncture 
modulates central nervous system processes,63 increasing the 
concentration of salivary neuropeptides, which seem capable 
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of  modulating the complex process of salivary secretion.64 
There are some studies that provide encouraging results, sug-
gesting an effective increase in salivary flow, while others do 
not detect statistically significant differences in the increase 
in salivary flow between the treated subjects and controls.65 
However, the results of systematic reviews do not indicate the 
efficacy of acupuncture in the treatment of xerostomia due to 
the current lack of relevant randomized clinical trials.64–67
When stimulation of salivary secretion fails, patients 
can be given palliative oral care in the form of application 
of mouthwashes and saliva substitutes. Although the daily 
use of a mouthwash or one of the saliva substitutes that 
are formulated to mimic natural saliva, is strongly recom-
mended, they do not stimulate salivary gland production. 
Commercially available products come in a variety of for-
mulations including solutions, sprays, gels, and lozenges. In 
general, they contain an agent to increase viscosity, such as 
carboxymethylcellulose or hydroxypropylmethylcellulose, 
hydroxyethylcellulose, and polyglycerylmethacrylate,65 
minerals such as calcium and phosphate ions and fluoride, 
preservatives such as methyl or propylparaben, and flavoring 
and related agents.
Also homeopathic remedies such as olive oil, aloe vera 
gel, and rape oil spray may be effective alternatives in the 
palliative management of xerostomic patients.68,69
In order to minimize problems related to the absence 
of or reduced secretion of saliva, all patients should be 
encouraged to take an active role in the management of 
their xerostomia; so a daily mouth examination, checking 
for red, white, or dark patches, ulcers, or tooth decay, is 
highly recommended.
Patients with reduced saliva should also be encouraged 
to consider visiting their dentist more frequently because 
they have got a greater susceptibility to dental problems. 
Teeth should be cleaned at least twice a day, so brushing 
and flossing regularly and the daily use of fluoride and 
chlorhexidine rinses may also be useful in preventing caries 
by reducing amounts of Streptococcus and Lactobacillus in 
the mouth. For daily use, a special dentifrice (eg, children’s 
toothpaste or anti-xerostomia dentifrices) is recommended, 
since the taste of a regular dentifrice may be too strong for 
these patients.
Dentures and acrylic appliances should not be worn 
during sleep and they should be kept clean by soaking 
them overnight in chlorhexidine. Sometimes, lubricants, 
Vaseline and/or glycerin based, put on the lips and under 
dentures, may relieve drying, cracking, soreness, and 
mucosal trauma.61
Patients with decreased salivary flow should also be made 
aware of the necessity to comply with suggested oral hygiene 
regimens after exposure to acid-producing food sources. Rec-
ommendations for professional and home fluoride treatments 
should be considered carefully for patients with salivary dys-
function, especially those with high caries rates and exposed 
root surfaces. A modified diet can be useful to minimize the 
effects of xerostomia; for instance, they should avoid sug-
ary or acidic foods and also avoid dry, spicy, astringent, or 
excessively hot or cold foods that are more irritating, while 
eating foods such as carrots or celery may also help patients 
with residual salivary gland function. The addition of flavor 
enhancers such as herbs, condiments, and fruit extracts may 
make food more palatable to patients complaining of their 
food tasting bland, papery, salty, or otherwise unpleasant; at 
the same time, taking frequent sips of water throughout the 
day and sucking on ice chips are helpful.70
Conclusion
The resulting salivary gland hypofunction and xerostomia 
arising from radiotherapy for HNC can cause a serious 
diseased condition. The stomatologic complications could 
depend on the type of cancer treatment and the cumulative 
radiation dose to the gland tissue. They can be reversible 
or irreversible, transient, or enduring. The best approach to 
manage the radiotherapeutic patient begins with a careful 
clinical assessment of the individual case, followed by pre-
ventive therapy aimed to reduce oral complications when 
possible. Therefore, the clinician must keep this kind of 
patients under careful control in order to palliate the symp-
toms of xerostomia and improve their quality of life.
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